ArticleClinical ophthalmology (Auckland, N.Z.)2020
Complete and Early Vitrectomy for Endophthalmitis After Cataract Surgery: An Alternative Treatment Paradigm.
Article in Clinical ophthalmology (Auckland, N.Z.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 49 citations in OpenAlex.
- Early vitrectomy and intravitreal antibiotics for post-operative exogenous endophthalmitis (EVIAN): a randomised control trial of feasibility.Communications medicine · 2026Article
- Efficacy and safety of intraocular lens removal combined with vitrectomy for acute endophthalmitis in pseudophakic eyes.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- Endoscope-assisted vitrectomy using a 25-gauge system for endophthalmitis: a case series.BMC ophthalmology · 2026Article
- Comparison of Clinical Outcomes of Intravitreal 0.625% Povidone-Iodine versus Antibiotic Injection for Postoperative Endophthalmitis.Korean journal of ophthalmology : KJO · 2026Article
- Pathogen-Associated Visual Outcomes Following Postprocedure Endophthalmitis.American journal of ophthalmology · 2026Article
- Areas of uncertainty in endophthalmitis care.World journal of clinical cases · 2026Review
- Endophthalmitis caused byInternational journal of ophthalmology · 2026Article
- From 1995 to now: the endophthalmitis vitrectomy study and the need for a contemporary evidence base.Eye (London, England) · 2025Article
- A rare case of exogenous fungal endophthalmitis following a traumatic corneal insult.BMC ophthalmology · 2025Article
- Controversies in the management of endophthalmitis: a 5-year retrospective cohort study.Journal of ophthalmic inflammation and infection · 2025Article
- Two-Decade Retrospective Analysis of Postoperative Endophthalmitis at a Tertiary Care Academic Center: Microbial Spectrum, Treatment Modalities, and Visual Outcomes.Clinical ophthalmology (Auckland, N.Z.) · 2025Article
- Design and Validation of Endophthalmitis Infectivity Measurement Algorithm in Post Cataract Acute Endophthalmitis: EMS Report No. 6.Translational vision science & technology · 2024Article
- Article
- Literature- and Experience-Based Consensus for Acute Post-operative Endophthalmitis and Endogenous Endophthalmitis in Taiwan.Ophthalmology and therapy · 2024Article
- Post-Cataract Surgery Fungal Endophthalmitis: 6-Year Experience in Management and Outcomes at a Tertiary Eye Care Center.Clinical ophthalmology (Auckland, N.Z.) · 2024Article
- Endogenous endophthalmitis due toClinical case reports · 2023Article
- Early Vitrectomy for Endophthalmitis: Are EVS Guidelines Still Valid?Ophthalmic research · 2023Review
- Early Vitrectomy: An Effective Treatment for Acute Postcataract Surgery Endophthalmitis.Advanced biomedical research · 2023Article
- Commentary: Usage of intravitreal steroids in endophthalmitis: Horns of a dilemma.Indian journal of ophthalmology · 2022Article
- Comment on: Real-life comparison of three intravitreal antibiotic drug regimens in endophthalmitis.Indian journal of ophthalmology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeIn this study, we report the treatment outcomes of complete and early vitrectomy for endophthalmitis (CEVE) after cataract surgery as the predominate initial treatment, accompanied by systemic antibiotics and retreatment of persistent or recurrent purulence (CEVE+). PATIENTS AND
methodsClinical features and microbiological factors were retrospectively reviewed in 62 eyes of 62 patients who were treated for acute postcataract endophthalmitis (APCE) occurring within three weeks of cataract surgery at Retina Specialists of Alabama, between 2007 and 2017.
resultsVisual acuity on presentation included light perception (LP) in 18 eyes (29%) and hand motion (HM) in 23 eyes (37%). Initial treatment was maximum possible vitrectomy in 48 eyes (77%) and tap-and-inject in 14 eyes (23%), with 38 eyes (61%) receiving two or more treatments. Cultures for the first intervention were positive in 49 eyes (79%) and virulent in 18 eyes (29%). At a median follow-up time of five months, final visual acuity was ≥20/40 in 49 eyes (79%), between 20/50 and 5/200 in seven eyes (11%), and <5/200 in six eyes (10%). Virulence was the strongest predictor of poor visual outcome. Retinal detachment occurred in four eyes (6%), likely from necrotic retinal defects in each case.
conclusionComplete and early vitrectomy is a safe and effective initial treatment for APCE. When accompanied by systemic antibiotics and retreatment (CEVE+) of recurrent media opacification, it improves recovery of 20/40 or better visual acuity by approximately 50% compared to a predominantly tap-and-inject treatment paradigm. We recommend CEVE for fundus-obscuring APCE (~75% of all cases) whenever the view is inadequate to rule out macular distress.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.